A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO)
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Dasatinib; Dexamethasone; Dexamethasone; Methotrexate; Ponatinib; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 24 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 12 May 2021 Status changed from not yet recruiting to recruiting.
- 17 Feb 2021 New trial record